Moberg Pharma AB (publ) (MOB.ST)
SEK 11.28
(10.37%)
SEK 11.28
(10.37%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | - SEK | -100.0% |
| 2022 | 207 Thousand SEK | 0.0% |
| 2021 | - SEK | -100.0% |
| 2020 | 33.65 Million SEK | 0.0% |
| 2018 | 439.04 Million SEK | 0.0% |
| 2017 | 439.03 Million SEK | 31.33% |
| 2016 | 334.3 Million SEK | 17.07% |
| 2015 | 285.56 Million SEK | 42.65% |
| 2014 | 200.18 Million SEK | 27.19% |
| 2013 | 157.38 Million SEK | 39.94% |
| 2012 | 112.46 Million SEK | 101.04% |
| 2011 | 55.94 Million SEK | 557.24% |
| 2010 | 8.51 Million SEK | 426.6% |
| 2009 | 1.61 Million SEK | 0.0% |
| 2008 | - SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 4.1 Million SEK | 401.1% |
| 2024 Q1 | 820 Thousand SEK | 0.0% |
| 2023 Q3 | - SEK | 0.0% |
| 2023 Q1 | - SEK | 0.0% |
| 2023 FY | - SEK | -100.0% |
| 2023 Q2 | - SEK | 0.0% |
| 2023 Q4 | - SEK | 0.0% |
| 2022 Q2 | - SEK | 0.0% |
| 2022 Q1 | - SEK | 0.0% |
| 2022 FY | 207 Thousand SEK | 0.0% |
| 2022 Q3 | 207 Thousand SEK | 0.0% |
| 2022 Q4 | - SEK | -100.0% |
| 2021 FY | - SEK | -100.0% |
| 2021 Q4 | - SEK | 0.0% |
| 2021 Q1 | - SEK | 100.0% |
| 2021 Q2 | - SEK | 0.0% |
| 2021 Q3 | - SEK | 0.0% |
| 2020 FY | 33.65 Million SEK | 0.0% |
| 2020 Q1 | 47.81 Million SEK | 1691.64% |
| 2020 Q4 | -16.82 Million SEK | 0.0% |
| 2020 Q2 | - SEK | -100.0% |
| 2020 Q3 | - SEK | 0.0% |
| 2019 Q4 | 2.66 Million SEK | -94.42% |
| 2019 Q1 | 15.55 Million SEK | -83.98% |
| 2019 Q3 | 47.81 Million SEK | 0.0% |
| 2019 Q2 | - SEK | -100.0% |
| 2018 Q2 | 141.88 Million SEK | 55.06% |
| 2018 FY | 439.04 Million SEK | 0.0% |
| 2018 Q4 | 97.06 Million SEK | -10.61% |
| 2018 Q3 | 108.59 Million SEK | -23.46% |
| 2018 Q1 | 91.5 Million SEK | 1.53% |
| 2017 Q3 | 108.28 Million SEK | -20.42% |
| 2017 FY | 439.03 Million SEK | 31.33% |
| 2017 Q1 | 104.55 Million SEK | 16.92% |
| 2017 Q4 | 90.12 Million SEK | -16.77% |
| 2017 Q2 | 136.07 Million SEK | 30.15% |
| 2016 FY | 334.3 Million SEK | 17.07% |
| 2016 Q1 | 69.45 Million SEK | 29.4% |
| 2016 Q2 | 71.29 Million SEK | 2.65% |
| 2016 Q3 | 104.13 Million SEK | 46.06% |
| 2016 Q4 | 89.42 Million SEK | -14.13% |
| 2015 FY | 285.56 Million SEK | 42.65% |
| 2015 Q1 | 73.17 Million SEK | 64.57% |
| 2015 Q3 | 66.56 Million SEK | -27.76% |
| 2015 Q2 | 92.15 Million SEK | 25.93% |
| 2015 Q4 | 53.67 Million SEK | -19.37% |
| 2014 Q4 | 44.46 Million SEK | -11.53% |
| 2014 Q2 | 57.7 Million SEK | 20.86% |
| 2014 Q1 | 47.74 Million SEK | 29.63% |
| 2014 FY | 200.18 Million SEK | 27.19% |
| 2014 Q3 | 50.26 Million SEK | -12.9% |
| 2013 FY | 157.38 Million SEK | 39.94% |
| 2013 Q4 | 36.83 Million SEK | -0.98% |
| 2013 Q3 | 37.19 Million SEK | -17.22% |
| 2013 Q2 | 44.93 Million SEK | 16.95% |
| 2013 Q1 | 38.42 Million SEK | 27.24% |
| 2012 Q2 | 24.5 Million SEK | -21.03% |
| 2012 Q1 | 31.02 Million SEK | 51.27% |
| 2012 FY | 112.46 Million SEK | 101.04% |
| 2012 Q4 | 30.19 Million SEK | 12.94% |
| 2012 Q3 | 26.73 Million SEK | 9.12% |
| 2011 Q2 | 8 Million SEK | 45.81% |
| 2011 Q4 | 20.51 Million SEK | -6.5% |
| 2011 Q3 | 21.93 Million SEK | 174.15% |
| 2011 Q1 | 5.48 Million SEK | 1.71% |
| 2011 FY | 55.94 Million SEK | 557.24% |
| 2010 Q1 | 603.98 Thousand SEK | 0.0% |
| 2010 FY | 8.51 Million SEK | 426.6% |
| 2010 Q3 | 2.29 Million SEK | 946.82% |
| 2010 Q4 | 5.39 Million SEK | 135.4% |
| 2010 Q2 | 218.98 Thousand SEK | -63.74% |
| 2009 FY | 1.61 Million SEK | 0.0% |
| 2008 FY | - SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| AcuCort AB | - SEK | NaN% |
| AlzeCure Pharma AB (publ) | - SEK | NaN% |
| BioGaia AB (publ) | 1.29 Billion SEK | 100.0% |
| Enzymatica AB (publ) | 50.9 Million SEK | 100.0% |
| Enorama Pharma AB (publ) | 1.35 Million SEK | 100.0% |
| Gabather AB (publ) | - SEK | NaN% |
| Klaria Pharma Holding AB (publ.) | - SEK | NaN% |
| Nanexa AB (publ) | 29.32 Million SEK | 100.0% |
| Newbury Pharmaceuticals AB (publ) | 36.82 Million SEK | 100.0% |
| ODI Pharma AB | 22.44 Million SEK | 100.0% |
| Orexo AB (publ) | 638.8 Million SEK | 100.0% |
| Probi AB (publ) | 627.68 Million SEK | 100.0% |
| Swedencare AB (publ) | 2.32 Billion SEK | 100.0% |
| Swedish Orphan Biovitrum AB (publ) | 22.12 Billion SEK | 100.0% |
| Toleranzia AB | 50.92 Million SEK | 100.0% |
| Vivesto AB | 1.01 Million SEK | 100.0% |